TABLE 2.
Effect of didanosine on buprenorphine and buprenorphine metabolites in plasma
| Pharmacokinetic parameter | Pre-didanosine | Post-didanosine | p value |
|---|---|---|---|
| Buprenorphine | |||
| AUC0–24 (ng h/ml) | 39.2 (6.6) | 35.2 (4.8) | 0.20 |
| Cl/F (L/h) | 507 (72) | 538 (73) | 0.50 |
| Cmax (ng/ml) | 4.89 (0.73) | 4.70 (0.45) | 0.76 |
| Tmax (h) | 1.0 (0.5–1.5) | 1.0 (0.5–1.5) | NS |
| Cmin (ng/ml) | 0.94 (0.21) | 0.87 (0.16) | 0.65 |
| Norbuprenorphine | |||
| AUC0–24 (ng h/ml) | 57.7 (10.9) | 57.2 (10.1) | 0.94 |
| Cl/F (L/h) | 343 (46) | 383 (74) | 0.34 |
| Cmax (ng/ml) | 4.18 (0.65) | 3.82 (0.45) | 0.41 |
| Tmax (h) | 1.5 (0.5–4) | 1.0 (0.5–6) | NS |
| Cmin (ng/ml) | 1.71 (0.41) | 2.05 (0.45) | 0.40 |
| Buprenorphine-3-glucuronide | |||
| AUC0–24 (ng h/ml) | 21.8 (6.0) | 19.5 (4.1) | 0.54 |
| Cl/F (L/h) | 1414 (379) | 1471 (388) | 0.48 |
| Cmax (ng/ml) | 5.94 (1.67) | 6.25 (1.39) | 0.85 |
| Tmax (h) | 0.5 (0.5–1.0) | 0.5 (0.5–1.5) | NS |
| Cmin (ng/ml) | 0.47 (0.13) | 0.40 (0.10) | 0.56 |
| Norbuprenorphine-3-glucuronide | |||
| AUC0–24 (ng h/ml) | 210 (48) | 210 (43) | 0.98 |
| Cl/F (L/h) | 107 (17) | 111 (22) | 0.76 |
| Cmax (ng/ml) | 16.8 (3.0) | 19.8 (3.9) | 0.24 |
| Tmax (h) | 2.0 (1.0–4) | 1.0 (0.5–2) | 0.02 |
| Cmin (ng/ml) | 5.59 (1.56) | 6.74 (1.58) | 0.30 |